Three misconceptions about JCA
Navigating Europe's Joint Clinical Assessment (JCA) process requires understanding what's required—and what's not. Many sponsors hold misconceptions about Joint Scientific Consultations, the relationship between JCA reports and national reimbursement decisions, and how EMA approval influences JCA outcomes.
Watch this video for more on the realities of the JCA process and how to develop a winning evidence generation strategy.
Related Insights
Video
JCA strategy: Predicting and prioritizing PICOs
Jan 22, 2026
Blog
Bolster your investor narrative with RWE
Jan 26, 2026
Report
New Medicines, Novel Insights: Achieving patient-guided drug development
Oct 30, 2023
Blog
Early Scientific Advice in cost effectiveness markets – how to navigate it and is it worth it?
Jun 14, 2023
Report
New Medicines, Novel Insights: Accelerating development of cell and gene therapies
May 22, 2023
Report
New Medicines, Novel Insights: Advancing rare disease drug development
May 22, 2023
Whitepaper
The Chinese Pharmaceutical Market: Size, R&D, Regulations, Market Access and Innovations
Mar 9, 2023
Playbook
Are you using real-world evidence?
Feb 1, 2023
Blog
U.S. price reforms 2022: How can drug manufacturers best prepare for the Inflation Reduction Act?
Aug 17, 2022
Blog
Innovative modeling method could speed patient access to critical IO therapies
Jan 4, 2023
Blog
Preparing for a new era in European Market Access
Jul 22, 2022
Webinar
China's Market Approval Policy and Medical Insurance Payment System for Rare Disease
Jul 21, 2022
Related Insights
Video
JCA strategy: Predicting and prioritizing PICOs
Jan 22, 2026
Blog
Bolster your investor narrative with RWE
Jan 26, 2026
Report
New Medicines, Novel Insights: Achieving patient-guided drug development
Oct 30, 2023
Blog
Early Scientific Advice in cost effectiveness markets – how to navigate it and is it worth it?
Jun 14, 2023
Report
New Medicines, Novel Insights: Accelerating development of cell and gene therapies
May 22, 2023
Report
New Medicines, Novel Insights: Advancing rare disease drug development
May 22, 2023
Whitepaper
The Chinese Pharmaceutical Market: Size, R&D, Regulations, Market Access and Innovations
Mar 9, 2023
Playbook
Are you using real-world evidence?
Feb 1, 2023
Blog
U.S. price reforms 2022: How can drug manufacturers best prepare for the Inflation Reduction Act?
Aug 17, 2022
Blog
Innovative modeling method could speed patient access to critical IO therapies
Jan 4, 2023
Blog
Preparing for a new era in European Market Access
Jul 22, 2022
Webinar
China's Market Approval Policy and Medical Insurance Payment System for Rare Disease
Jul 21, 2022